Everest Organics Ltd Downgraded to Sell Amid Mixed Financial and Valuation Signals

Quality Assessment: A Mixed Picture

Everest Organics operates within the Pharmaceuticals & Biotechnology sector, classified as a micro-cap with a current market price of ₹234.00, down 5.34% on the day. The company’s quality grade remains low, consistent with its Mojo Grade of Sell (upgraded from Strong Sell), and a Mojo Score of 31.0. This reflects ongoing concerns about its fundamental strength and operational efficiency.

Over the last five years, Everest Organics has exhibited a negative compound annual growth rate (CAGR) of -7.30% in operating profits, signalling weak long-term fundamental strength. The average return on equity (ROE) stands at a modest 2.02%, indicating limited profitability relative to shareholders’ funds. Additionally, the company’s ability to service debt is constrained, with a high Debt to EBITDA ratio of 2.52 times, raising questions about financial resilience.

However, some recent financial metrics show promise. The return on capital employed (ROCE) for the half-year period has reached 9.86%, the highest recorded, suggesting improved capital efficiency. The debt-equity ratio has also decreased to a low 0.68 times, indicating a more conservative capital structure. These factors contribute positively to the quality assessment, albeit insufficient to fully offset the broader concerns.

Valuation Upgrade: From Attractive to Very Attractive

The most significant positive shift in Everest Organics’ rating stems from its valuation metrics. The valuation grade has been upgraded from attractive to very attractive, reflecting the stock’s compelling price multiples relative to its peers and historical benchmarks.

Key valuation ratios include a price-to-earnings (PE) ratio of 40.34, which, while elevated, is accompanied by a remarkably low price-to-earnings-growth (PEG) ratio of 0.08, signalling that earnings growth potential is not fully priced in. The price-to-book value stands at 2.97, and enterprise value to EBITDA is 13.81, both indicating reasonable valuation levels within the pharmaceuticals sector.

Compared to peers such as Bliss GVS Pharma and Kwality Pharma, which are rated very expensive with PE ratios around 35.58 and EV/EBITDA multiples exceeding 20, Everest Organics offers a more attractive entry point. Its ROCE of 10.68% and ROE of 7.37% further support this valuation upgrade, suggesting that the company’s capital is being deployed efficiently relative to its market price.

Financial Trend: From Positive to Flat

Despite the valuation improvement, Everest Organics’ financial trend has deteriorated from positive to flat over the last quarter ending March 2026. The financial score dropped sharply from +8 to -2 in the past three months, reflecting a slowdown in growth momentum.

On the positive side, the company reported a quarterly profit after tax (PAT) of ₹2.63 crores, an 80.1% increase compared to the previous four-quarter average. Profit before tax excluding other income (PBT less OI) rose by 45.9% to ₹2.01 crores, and operating profit before depreciation and interest (PBDIT) reached a quarterly high of ₹6.70 crores. The operating profit to net sales ratio also improved to 13.74%, the highest recorded.

However, these gains are tempered by weaker six-month PAT growth of -26.17%, signalling recent earnings pressure. The operating profit to interest coverage ratio fell to a low of 2.43 times, indicating reduced ability to comfortably service interest expenses, which themselves rose to a quarterly high of ₹2.76 crores. Additionally, the debtors turnover ratio declined to 1.63 times, suggesting slower collection efficiency.

These mixed financial signals explain the flat trend rating, highlighting the company’s struggle to maintain consistent profitability and operational efficiency despite some quarterly improvements.

Technicals and Market Performance

Technically, Everest Organics has underperformed the broader market over multiple time horizons. Year-to-date, the stock has declined by 53.74%, significantly worse than the Sensex’s 12.76% fall. Over the past year, the stock’s return was -45.20%, compared to the Sensex’s -7.92%. Even over five years, the stock has lost 37.44%, while the Sensex gained 42.34%.

Despite this underperformance, the stock’s long-term return over ten years remains impressive at 800%, far outpacing the Sensex’s 176.97%. This suggests that while recent performance has been weak, the company has delivered substantial value over the long term.

Price-wise, Everest Organics is trading near its 52-week low of ₹197.00, well below its 52-week high of ₹536.40, indicating significant price correction and potential value opportunity for investors willing to tolerate volatility.

Summary and Outlook

Everest Organics Ltd’s upgrade from Strong Sell to Sell reflects a complex interplay of factors. The company’s valuation has become very attractive relative to peers, supported by improved capital efficiency and a low PEG ratio. However, the financial trend has flattened, with mixed quarterly results and ongoing challenges in profitability and debt servicing.

Quality metrics remain subdued, with weak long-term profit growth and modest returns on equity. The stock’s technical performance has lagged the broader market, though its long-term returns remain noteworthy. Investors should weigh the company’s attractive valuation against its operational and financial headwinds.

Given these considerations, Everest Organics may appeal to value-oriented investors with a higher risk tolerance, while those seeking stable growth and stronger fundamentals might explore alternative opportunities within the pharmaceuticals sector.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today